EXTON, Pa.--(BUSINESS WIRE)--Absorption Systems, LP, today announced the online publication of a scientific manuscript in one of the leading journals in the field of drug metabolism and pharmacokinetics, Drug Metabolism and Disposition. The paper describes the engineering of Absorption Systems’ proprietary test system for measuring drug efflux, the cell’s mechanism for expelling substances, including pharmaceuticals, as it relates to Human Breast Cancer Resistance Protein, or hBCRP. The over-expression of hBCRP in cancer cells is an important mechanism contributing to tumor resistance to chemotherapeutic drugs. In normal physiology, hBCRP helps reduce exposure of sensitive tissues, such as the placenta, testis and brain, to potentially toxic chemicals ingested in the diet Evaluation of hBCRP may help researchers better understand patient response to chemotherapeutics used to treat breast cancer or interactions between co-administered therapeutic drugs or drugs and dietary supplements, such as herbal products.
